Todd Campbell

Todd Campbell

TMFEBCapital

Todd has been helping buy side portfolio managers as an independent researcher for over a decade. In 2003, Todd founded E.B. Capital Markets, LLC, a research firm providing action oriented ideas to professional investors. Todd has provided insight to a variety of publications, including SmartMoney, Barron's, and CNN/fn.

Recent articles









Should You Buy Celgene Stock?

Celgene's fallen out of favor with investors, but drugs currently in development might make buying its shares smart.


DexCom Stock History

Here's how this small medical device company is helping to tackle diabetes and why it might be worth buying in your portfolio.



Social Security's AIME: What Is It?

Understanding Social Security's average indexed monthly earnings calculation is important if you want to know how much money you can receive in Social Security income.


Why Nektar Therapeutics Stock Stumbled 11.8% Today

Shares have been on a roller-coaster ride since the company presented updated study results for its latest drug and outlined its goals at an investor conference on Wednesday.



Why I Just Bought These 3 Stocks

There are thousands of publicly traded stocks, but I settled on adding these three to my portfolio this month.